Product Categories

BI 2536

BI 2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM.

Catalog No.S1109
5 5 10 Reviews 14 Product Citations
Price Stock Quantity  
USD 120 In stock
USD 210 In stock
USD 670 In stock
USD 1070 In stock
Contact Us Bulk Inquiry Add to Wishlist

Free Overnight Delivery on all orders over $ 500.

Order now and get it on

Tel: +1-832-582-8158[email protected]

BI 2536 Chemical Structure
Molecular Weight: 521.66

Validation & Quality Control

Customer Reviews(10)

Quality Control & MSDS

Related Compound Libraries

BI 2536 is available in the following compound libraries:

Cambridge Cancer Compound Library(96-well) Chemical Library (96-well) Inhibitor Library (96-well) Kinase Inhibitor Library (96-well)

Product Information

  • Compare PLK Inhibitors
    Compare PLK Inhibitors
  • Research Area
  • BI 2536 Mechanism

Product Description

Biological Activity Protocol Chemical Information Customer Reviews Product Citations Tech Support & FAQs

Biological Activity

Description BI 2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM.
Targets Plk1
IC50 0.83 nM [1]
In vitro BI 2536 blocks the activities of Plk2 and Plk3 to a slightly lesser extent with IC50 of 3.5 nM and 9.0 nM, respectively. In HeLa cells, BI 2536 treatment ranging from 10-100 nM leads to the blocking of the recruitment of γ-tubulin and phosphorylation of Apc6 at mitotic centrosomes, inhibition of cohesin release from chromosome arms, induction of monopolar spindles, as well as a range of other mitotic processes that are known to depend on Plk1. BI 2536 treatment leads to the HeLa cells arrested in G2/M, subsequently a sub-G1 DNA peak indicative of DNA breakdown and apoptosis, and accumulated cleaved PARP p85 fragments in a concentration-dependent manner. BI 2536 inhibits the growth of a panel of 32 human cancer cell lines with EC50 of 2-25 nM, while blocking the proliferation of exponentially growing hTERT-RPE1, human umbilical vein endothelial cells (HUVECs), and normal rat kidney (NRK) cells with EC50 of 12-31 nM. [1] Plk1 inhibition by BI 2536 reduces the growth and viability of anaplastic thyroid carcinoma (ATC) cells such as CAL62, OCUT-1, SW1736, 8505C, and ACT-1 with EC50 values of 1.4-5.6 nM. [2]
In vivo BI 2536 given i.v. once or twice per week is highly efficacious in diverse xenograft models with acceptable tolerability by inhibiting cell proliferation through a mitotic arrest, and subsequently induction of tumor-cell death. Administration of BI 2536 at 50 mg/kg once or twice per week significantly inhibits growth of HCT 116 xenografts with T/C of 15% and 0.3%, respectively. BI 2536 treatment twice-weekly also leads to excellent tumor-growth in BxPC-3 and A549 models with T/C of 5% and 14%, respectively. [1]
Clinical Trials A Phase II study of BI 2536 infusional treatment in patients over 60 years of age with refractory or relapsed acute myeloid leukaemia has been completed.
Features BI 2536 is the first potent and selective Plk1 inhibitor that induces all hallmarks of Plk1 inhibition.

Protocol(Only for Reference)

Kinase Assay: [1]

Plk1 in vitro kinase assay Recombinant human Plk1 (residues 1-603) is expressed as N-terminal, GST-tagged fusion protein with a baculoviral expression system and purified by affinity chromatography with Glutathione-agarose. Enzyme activity assays for Plk1 are performed in the presence of serially diluted BI 2536 with 20 ng of recombinant kinase and 10 μg casein from bovine milk as the substrate. Kinase reactions are performed in a final volume of 60 μL for 45 minutes at 30 °C (15 mM MgCl2, 25 mM MOPS [pH 7.0], 1 mM DTT, 1% DMSO, 7.5 mM ATP, 0.3 μCi γ-33P-ATP). Reactions are terminated by the addition of 125 μL of ice-cold 5% TCA. After transfer of the precipitates to Multi-Screen mixed ester cellulose filter plates, plates are washed with 1% TCA and quantified radiometrically. Dose-response curve is used for calculating IC50 value.

Cell Assay: [1]

Cell lines HeLa, A43, SKOV-3, HT-29, K562, A549, Saos-2, MCF7, HCT116, COLO 205, Hep G2, Raji and PC-3 cells, etc.
Concentrations Dissolved in DMSO, final concentrations ~1 μM
Incubation Time 24 and 72 hours
Method Cells are exposed to various concentrations of BI 2536 for 24, and 72 hours. Cell growth is assessed by the measurement of Alamar Blue dye conversion in a fluorescence spectrophotometer. For determining the DNA content of the cultures, cell suspensions are fixed in 80% ethanol, treated for 5 minutes with 0.25% Triton X-100 in PBS, and incubated with 0.1% RNase and 10 μg/mL propidium iodide (PI) in PBS for 20 minutes at RT. Cell-cycle profiles are determined by flow cytometric analysis.

Animal Study: [1]

Animal Models Female BomTac:NMRI-Foxn1nu mice injected subcutaneously with HCT 116, NCI-H460, or A549 cells
Formulation Formulated in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl
Dosages ~50 mg/kg
Administration Injection i.v. once or twice per week
1

References

Chemical Information

Download BI 2536 SDF
Molecular Weight (MW) 521.66
Formula

C28H39N7O3
CAS No. 755038-02-9, 876126-71-5 (H2O)
Synonyms N/A
Solubility (25°C)
  • DMSO 96 mg/mL
  • Water <1 mg/mL
  • Ethanol 104 mg/mL
Storage 2 years -20°CPowder
2 weeks4°Cin DMSO
6 months-80°Cin DMSO
Chemical Name (R)-4-(8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-ylamino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide
Molarity Calculator Dilution Calculator Molecular Weight Calculator

Research Area

Customer Reviews (10)


Click to enlarge 		Rating
Source Cancer Res, 2011, 71, 1385-1395. BI 2536 purchased from Selleck
Method Tumor growth assay
Cell Lines NOD/SCID mice
Concentrations 12.5-25 mg/kg
Incubation Time 0-24 d
Results As shown in Figure A,tumor growth was significantly inhibited following administration of the third cycle of BI 2536 therapy. When mice were administered 25 mg/ kg weekly on 2 consecutive days for a total of only 2 cycles, tumor growth was inhibited after the second cycle ( Fig. B)

Click to enlarge 		Rating
Source Cancer Res, 2011, 71, 1385-1395. BI 2536 purchased from Selleck
Method Tumor growth assay
Cell Lines NOD/SCID mice
Concentrations 12.5 mg/kg
Incubation Time 0-60 d
Results We examined a combination of a low dose of BI 2536 (12.5 mg/kg) with a low dose of irinotecan (10 mg/kg), a topoisomerase inhibitor with demonstrated activity in phase II clinical trials in relapsed NB. Single-agent treatment with low-dose of either BI 2536 or irinotecan was comparably efficacious, resulting in significant growth inhibition, as compared with vehicle-treated animals.

Click to enlarge 		Rating
Source J Biomol Screen, 2013, 18(1), 54-66. BI 2536 purchased from Selleck
Method 3D Tumor Growth Assay
Cell Lines PC-3M cells
Concentrations 0-10uM
Incubation Time 7 d
Results Reduction of colony size was observed for a number of established anticancer drugs, and IC 50 values for those reference compounds were determined based on the average area size of the cluster. IC 50 values were determined in two independent experiments and were quite reproducible.

Click to enlarge 		Rating
Source J Biomol Screen, 2013, 18(1), 54-66. BI 2536 purchased from Selleck
Method 3D Tumor Growth Assay
Cell Lines PC-3M cells
Concentrations 10uM
Incubation Time 7 d
Results Reduction of colony size was observed for a number of established anticancer drugs, and IC 50 values for those reference compounds were determined based on the average area size of the cluster. IC 50 values were determined in two independent experiments and were quite reproducible.

Click to enlarge 		Rating
Source J Biol Chem, 2012, 287(21), 17088-99.. BI 2536 purchased from Selleck
Method Cell death assay
Cell Lines HeLa cells
Concentrations 0 -120 nM
Incubation Time 72 h
Results In HeLa cells lacking GRK5, there was an~4.5-fold decrease in the EC50 of BI 2536-mediated cell death (control shRNA, 18.9 ?.2 nM; GRK5 shRNA, 4.1?.1 nM, n = 6, p < 0.05) (Fig. A). Similar to BI 2536, cells lacking GRK5 were ~4.5-fold more sensitive to GSK461364 compared with control cells (EC50 for control shRNA cells, 17.0 ?4.4 nM;EC50 for GRK5-shRNA cells, 3.8 ?0.7 nM, n = 4, p < 0.05).

Click to enlarge 		Rating
Source J Invest Dermatol, 2011, 131, 1886–1895. BI 2536 purchased from Selleck
Method MTT assay
Cell Lines M14 cell lines, WM-115 cell lines
Concentrations 1-20 nM
Incubation Time
Results Specific inhibition of Plk-1 using the commercially available inhibitor BI 2536 led to a dose- and time-dependent decrease in human melanoma cell viability.

Click to enlarge 		Rating
Source Nat Cell Biol, 2011, 13, 1265-71. BI 2536 purchased from Selleck
Method cold-stable assay, Immunological methods
Cell Lines RPE1 cells
Concentrations 40 nM
Incubation Time 45 min
Results To examine whether B56-PP2A attenuates the signalling of kinetochore kinases other than Aurora B, we examined Plk1. Remarkably, wash-in of the Plk1 inhibitor BI2536 also restored K-fibres in B56-PP2A-siRNA cells.

Click to enlarge 		Rating
Source Cancer Cell , 2010, 18, 641–654. BI 2536 purchased from Selleck
Method Immunohistochemical analysis
Cell Lines SCID mice
Concentrations
Incubation Time
Results Control tumors grow exponentially, whereas genetic ablation of Cdc20 results in complete tumor regression in about 10 days. In comparison, treatment with taxol, vincristine, and BI2536 only induces partial responses ( Figure C). In agreement with the data observed in vitro, immunohistochemical analysis of samples taken 3 days after the first treatment indicates lack of proliferation (as measured by BrdU incorporation) and massive apoptosis in Cdc20 null cells, whereas all other samples maintain significant levels of proliferation and reduced apoptotic markers ( Figure D)

Click to enlarge 		Rating
Source Cancer Res, 2011, 71, 1385-1395. BI 2536 purchased from Selleck
Method Western blot
Cell Lines NB TICs
Concentrations 10-100 nM
Incubation Time 16/24 h
Results The cyclin-dependent kinase inhibitor p21, a newly identified substrate of PLK1, also accumulated in BI 2536-treated NB TICs (Fig. C). Finally, PLK1 kinase activity was inhibited following treatment of NB TICs with BI 2536, as demonstrated by anti-PLK1 immunoprecipitiation followed by in vitro PLK1 kinase assay ( Fig. D)

Click to enlarge 		Rating
Source Cancer Res, 2011, 71, 1385-1395. BI 2536 purchased from Selleck
Method Trypan blue exclusion, Western blot
Cell Lines NB TICs
Concentrations 10/30/100 nmol/L
Incubation Time 24/48/72 h
Results We observed a significant difference in viable cell numbers in BI2536-treated samples, as compared with DMSO (vehicle)-treated cells, at 24 hours posttreatment. The difference became more pronounced with time, such that at 72 hours there were only approximately 20% viable cells following treatment with 10 nmol/L BI 2536 and approximately 2% to 5% viable cells following treatment with 30 and 100 nmol/L as compared with DMSO-treated cells(Fig. A). At 24 hours, BI 2536-treated cells gradually accumulated cleaved PARP, in contrast to DMSO-treated cells, suggesting induction of apoptosis ( Fig. B).

Product Citations (14)

  • Systematic discovery of TLR signaling components delineates viral-sensing circuits. [Chevrier N, et al. Cell 2011;147(4), 853-867]

    PubMed: 22078882

  • Targeting mitotic exit leads to tumor regression in vivo: modulation by Cdk1, Mastl, and the PP2A/B55α,δ phosphatase. [Manchado E, et al. Cancer Cell 2010;18(6), 641-654]

    PubMed: 21156286

  • Formation of stable attachments between kinetochores and microtubules depends on the B56-PP2A phosphatase. [Foley EA, et al. Nat Cell Biol 2011;13(10), 1265-1271]

    PubMed: 21874008

  • SLAIN2 links microtubule plus end-tracking proteins and controls microtubule growth in interphase. [van der Vaart B, et al. J Cell Biol 2011;193(6), 1083-1099]

    PubMed: 21646404

  • Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. [Grinshtein N, et al. Cancer Res 2011;71(4), 1385-1395]

    PubMed: 21303981

  • Small RNA sequencing and functional characterization reveals microRNA-143 tumor suppressor activity in liposarcoma. [Ugras S, et al. Cancer Res 2011;71(17), 5659-5669]

    PubMed: 21693658

  • Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinoma. [Watt SA, et al. Oncogene 2011;30(46), 4666-4677]

    PubMed: 21602893

  • Polo-like kinase 1 is a potential therapeutic target in human melanoma. [Jalili A, et al. J Invest Dermatol 2011;131(9), 1886-1895]

    PubMed: 21654832

  • Centrosomal Protein 55 (Cep55) Stability Is Negatively Regulated by p53 Protein through Polo-like Kinase 1 (Plk1). [Chang YC, et al. J Biol Chem 2012;287(6):4376-85]

    PubMed: 22184120

  • G protein-coupled receptor kinase 5 phosphorylates nucleophosmin and regulates cell sensitivity to polo-like kinase 1 inhibition. [So CH, et al. J Biol Chem 2012;287(21):17088-99]

    PubMed: 22467873

  • The Centrosomal Kinase Plk1 Localizes to the Transition Zone of Primary Cilia and Induces Phosphorylation of Nephrocystin-1. [Seeger-Nukpezah T, et al. PLoS One 2012;7(6):e38838]

    PubMed: 22701722

  • Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53. [Meng X, et al. Gynecol Oncol 2013;128(3):461-9]

    PubMed: 23146687

  • Tools to discriminate between targets of CK2 vs PLK2/PLK3 acidophilic kinases. [Salvi M, et al. Biotechniques 2012;]

    PubMed: 23066668

  • Translation of a Tumor Microenvironment Mimicking 3D Tumor Growth Co-culture Assay Platform to High-Content Screening. [Krausz E, et al. J Biomol Screen 2013;18(1):54-66]

    PubMed: 22923784

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions
Tel: +1-832-582-8158 Ext:3Monday–Friday 9:00 AM–5:00 PM (Central Time)

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related PLK Inhibitors

  • TAK-960

    TAK-960 is a novel, potent and selective Plk1 inhibitor with IC50 of 8 nM.

  • Rigosertib (ON-01910)

    Rigosertib (Estybon, Novonex, ON-01910) is a non-ATP-competitive inhibitor of PLK1 (Polo-like kinase 1) with IC50 of 9 nM.

  • HMN-214

    HMN-214 (IVX-214) is a potent inhibitor of Polo-like kinase (Plk)1 with IC50 of 118 nM.

  • GSK461364

    GSK461364 inhibits purified Plk1 with Ki of 2 nM.

  • BI6727 (Volasertib)

    BI6727 (Volasertib) is a highly potent Plk1 inhibitor with IC50 of 0.87 nM.

  • MLN0905

    MLN0905 is a potent inhibitor of PLK1 with IC50 of 2 nM.

  • VX-680 (MK-0457, Tozasertib)

    VX-680 (MK-0457, Tozasertib) is a pan-Aurora inhibitor of Aurora A, Aurora B and Aurora C with Kiapp of 0.6 nM, 18 nM and 4.6 nM, respectively.

  • Y-27632 2HCl

    Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with Ki of 140 nM.

  • MLN8054

    MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM.

  • ZM-447439

    ZM-447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively.

Cell Cycle and DNA Damage Related Products

> Download

Recently Viewed Items

Tags: buy BI 2536 | BI 2536 supplier | purchase BI 2536 | BI 2536 cost | BI 2536 manufacturer | order BI 2536 | BI 2536 distributor
Contact Us